AQR Capital Management’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$884K Buy
26,180
+15,098
+136% +$595K ﹤0.01% 3131
2026
Q2
$427K Buy
+11,082
New +$338K ﹤0.01% 3463
2024
Q4
– Sell
-10,082
Closed -$287K – 2903
2024
Q3
$287K Sell
10,082
-76,201
-88% -$2.25M ﹤0.01% 2411
2024
Q2
$2.28M Sell
86,283
-2,315
-3% -$65.8K ﹤0.01% 1405
2024
Q1
$2.86M Buy
88,598
+19,634
+28% +$716K ﹤0.01% 1242
2023
Q4
$2.91M Buy
68,964
+43,270
+168% +$1.59M 0.01% 1182
2023
Q3
$986K Sell
25,694
-34,532
-57% -$781K ﹤0.01% 1604
2023
Q2
$1.14M Buy
60,226
+35,501
+144% +$662K ﹤0.01% 1498
2023
Q1
$383K Buy
+24,725
New +$429K ﹤0.01% 1865

Other funds holding IMVT

AQR Capital Management's IMVT Position: Q3 2026 in Review

AQR Capital Management increased its Immunovant (IMVT) stake by 136% in Q3 2026, buying an estimated $595K and bringing the position to 26,180 shares worth $884K. The position accounts for ﹤0.01% of the portfolio, ranked #3131.

AQR Capital Management first reported a position in IMVT in Q1 2023 and has held it in 9 quarters since. The position peaked at $2.91M in Q4 2023. 232 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • AQR Capital Management held 26,180 shares of Immunovant worth $884K as of Q3 2026.
  • AQR Capital Management bought 15,098 Immunovant shares in Q3 2026, an estimated $595K.
  • Immunovant made up ﹤0.01% of AQR Capital Management's portfolio in Q3 2026, its #3131 holding.
  • AQR Capital Management first reported a position in Immunovant in Q1 2023 and has held it in 9 quarters since.
  • AQR Capital Management's Immunovant position peaked at $2.91M in Q4 2023.
  • 232 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on AQR Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.